Perspectives in adjuvant treatment of prostate cancer

Urologia Internationalis

Volumn 68, Issue 1, 2002, Pages 1-5

  Wirth, Manfred P ^a   Froehner, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG TOLERABILITY; EARLY CANCER; HEALTH PROGRAM; HUMAN; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036151613     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048409     Document Type: Review

References (28)

1. The results of prostate carcinoma creening in the US as reflected in the surveillance, epidemiology, and end results program
2. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
3. Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis
4. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer
5. VACURG studies of conservative treatment
6. Osteoporosis after orchiectomy for prostate cancer
7. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up
8. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer
9. Adjuvant and neoadjuvant hormonal therapy for prostate cancer
10. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
11. Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland
12. Studies on prostatic cancer. III. The effect of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate
13. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment
14. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Reseach Council trial
15. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
16. Early androgen ablation for prostate cancer?
17. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation
18. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
19. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study
20. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy - Report of RTOG protocol 85-31
21. Management of locally advanced prostate cancer 2. Radio-therapy, neoadjuvant endocrine treatment, up-date 1997-1999
22. Androgen ablation in addition to radiation therapy for prostate cancer: Is there a true benefit?
23. Neoadjuvant hormonal therapy in carcinoma of the prostate
24. A review of studies of hormonal adjuvant therapy in prostate cancer
25. Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule
26. Adjuvant antiandrogenic treatment after radical prostatectomy in stage C prostate cancer - Preliminary results of a randomized controlled multicenter trial
27. Bicalutamide ('Casodex') early prostate cancer program: Final demographic data from over 8,000 randomized patients
28. The bicalutamide early prostate cancer program. Demography